激素冲击联合奥曲肽球后注射治疗甲状腺相关眼病
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Observation of curative effect of methylprednisolone with octreotide retrobulbar injection therapy on thyroid associated ophthalmopathy
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:探讨甲基强的松龙冲击联合奥曲肽球后注射治疗甲状腺相关眼病的临床效果。

    方法:对51例96眼甲状腺相关眼病患者以甲基强的松龙500mg静滴,连用3d; 后改用奥曲肽0.1mg球后注射1次,连续注射3次。疗程结束后1,3mo随访观察记录患者自觉症状及眼部体征。

    结果:患者49例症状均有明显改善或消失。治疗后患眼平均眼球突出度下降3.1±1.4mm,睑裂高度下降2.4±0.9mm ,治疗前后差异均有统计学意义(P<0.05)。

    结论:激素冲击联合奥曲肽球后注射治疗甲状腺相关眼病效果明显,不良反应小,安全可靠。

    Abstract:

    AIM: To explore the curative effect of methylprednisolone with octreotide retrobulbar injection therapy on thyroid associated ophthalmopathy.

    METHODS:Fifty-one cases(96 eyes)with thyroid associated ophthalmopathy were treated with methylprednisolone(500mg/d)for 3d, and then retrobulbar injection of octreotide(0.1mg/mo)for 3mo in one course. Symptoms and signs of the patients were observed before and after the treatment course.

    RESULTS: Symptoms of 49 cases were improved significantly. In all cases, the mean value of exophthalmus of the patients was significantly decreased after the treatment by 3.1±1.4mm. The height of palpebral fissure was significantly decreased after the treatment by 2.4±0.9mm, there were statistically significant difference before and after treatment(P<0.05).

    COCLUSION:Methylprednisolone with octreotide retrobulbar injection therapy can improve symptoms and signs of the patients with thyroid associated ophthalmopathy with high safety and no obvious side effect.

    参考文献
    相似文献
    引证文献
引用本文

彭细峰,姜文浩,颜坚,等.激素冲击联合奥曲肽球后注射治疗甲状腺相关眼病.国际眼科杂志, 2014,14(10):1906-1907.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2014-05-24
  • 最后修改日期:2014-09-10
  • 录用日期:
  • 在线发布日期: 2014-09-22
  • 出版日期:
文章二维码